Cevira

Cevira is a non-surgical treatment option for women with high-grade cervical dysplasia, a precancerous condition that can lead to cervical cancer. It is developed by the Norwegian biopharmaceutical company Photocure.

Overview

Cevira is a drug-device product that uses a combination of a photosensitizing drug and a specially designed device to deliver the drug to the affected area. The drug is activated by light from the device, which triggers a reaction that destroys the abnormal cells without harming the healthy tissue. This process is known as photodynamic therapy (PDT).

Mechanism of Action

The active ingredient in Cevira is aminolevulinic acid (ALA), which is a precursor to protoporphyrin IX (PpIX). When ALA is applied to the tissue, it is taken up by the abnormal cells and converted into PpIX. The device then emits light at a specific wavelength that activates the PpIX, causing it to produce reactive oxygen species that destroy the cells.

Clinical Trials

Cevira has undergone several clinical trials to evaluate its safety and efficacy. In a phase 2b trial, it was found to be effective in treating high-grade cervical dysplasia, with a complete response rate of 66% at 12 months. A phase 3 trial is currently underway.

Potential Benefits

Cevira offers several potential benefits over traditional treatment options for high-grade cervical dysplasia, such as surgery. It is a non-invasive treatment that can be administered in an outpatient setting, and it preserves the cervical tissue, which is important for women who wish to have children in the future.

See Also

• Photodynamic therapy
• Cervical dysplasia
• Cervical cancer
• Photocure

References

‎